Post Concussive Headache Clinical Trial
Official title:
Protective Headache Factors for Migraineurs and Postconcussive Headache Patients: Are Behavioral Strategies Effective? A Naturalistic Study
NCT number | NCT02748174 |
Other study ID # | 15-01055 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2016 |
Est. completion date | April 2018 |
Verified date | December 2018 |
Source | New York University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a naturalistic study of 100 migraineurs and 75 post concussive headache patients who will be asked to record their headaches, medications, sleep and other behaviors in a smartphone app called Curelator. The software was developed to identify possible headache triggers. We seek to determine whether there might be protective headache factors. Patients will be given audio files with relaxation therapies. We seek to understand whether this self relaxation therapy and/or traditional evidence based behavioral treatment recommended during a patient visit is protective against migraine attacks.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 2018 |
Est. primary completion date | April 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female reporting at least 6 month history of episodic or chronic migraine with 6-20 headache days a month - Age: 18-65 years - Age of onset of migraine was <age 50 - Able to give informed consent/assent - Sufficiently fluent in English to be able to use the English language version of Curelator Headache (no translations available). - Has ownership of or reliable access to iPhone or (mini) iPad running iOS 7 or higher - Able to give written informed consent (adults), or, for adolescents, has a parent/caregiver who can give informed consent and adolescent is able to give assent. - Willing to use Curelator Headache for at least 3 months and to comply with study procedures. - In the Investigator's opinion, there is no reason to believe that Curelator Headache use would pose any risk to the patient. Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
United States | New York University Langone Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
New York University School of Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of completers (assessment of adherence) | 90 Days | ||
Primary | Number of days with migraine and other headache | 90 Days | ||
Primary | Number of migraine headaches | 90 Days | ||
Primary | Number of significant trigger/warning sign - migraine attack associations | This will be analyzed by means of univariate Cox Proportional Hazards (PH) models. At the end of the study period (Day 90) significant trigger factors (HR/RR>1 and p-value = 0.05) will be identified for each individual: the number and percentage of subjects with at least one significant relationship between a trigger and occurrence of migraine attacks and the number of trigger-migraine attack significant relationships per individual will be estimated by means of descriptive statistics. | 90 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00237705 -
Intravenous Metoclopramide for the Treatment of Post Concussive Headache: a Randomized Placebo Controlled Trial
|
N/A |